Alterations in plasma hyaluronic acid in patients with clinically stable COPD versus (non)smoking controls

Abstract Hyaluronic acid (HA) is a key component of the extracellular matrix. HA and its metabolism are suggested to be altered in the lungs of patients with chronic obstructive pulmonary disease (COPD). The present study explored systemic HA, and its metabolic regulators, in patients with clinicall...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kiki Waeijen-Smit, Niki L. Reynaert, Rosanne J. H. C. G. Beijers, Sarah Houben-Wilke, Sami O. Simons, Martijn A. Spruit, Frits M. E. Franssen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/68d5b36613634f9f9ad5b73c168b0ad3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:68d5b36613634f9f9ad5b73c168b0ad3
record_format	dspace
spelling	oai:doaj.org-article:68d5b36613634f9f9ad5b73c168b0ad32021-12-02T14:53:35ZAlterations in plasma hyaluronic acid in patients with clinically stable COPD versus (non)smoking controls10.1038/s41598-021-95030-62045-2322https://doaj.org/article/68d5b36613634f9f9ad5b73c168b0ad32021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-95030-6https://doaj.org/toc/2045-2322Abstract Hyaluronic acid (HA) is a key component of the extracellular matrix. HA and its metabolism are suggested to be altered in the lungs of patients with chronic obstructive pulmonary disease (COPD). The present study explored systemic HA, and its metabolic regulators, in patients with clinically stable COPD and smoking and non-smoking controls. Furthermore, associations of HA with acute exacerbations (AECOPD), airway-related hospitalizations, systemic inflammation and cardiovascular risk were studied. In total, 192 patients with moderate to very severe COPD [aged 62.3 y (± SD 7.0)], 84 smoking controls [aged 61.8 y (± 5.7)], and 107 non-smoking controls [aged 60.1 y (± 7.0)] were included. Plasma HA was reduced in patients with COPD compared to non-smoking controls (p = 0.033), but was comparable after adjusting for age and sex. Expression of HAS-3 did not differ between groups, but was substantially less detectable in more patients with COPD than (non)smoking controls (p < 0.001). Expression of HYAL-2 was enhanced in patients with COPD versus smoking (p = 0.019) and non-smoking (p < 0.001) controls, also in the age- and sex- adjusted model (p < 0.001). Plasma HA was not associated with AECOPD, airway-related hospitalizations in the previous year, or systemic inflammation in COPD. Arterial pulse wave velocity explained some of the variance (< 10%) in plasma HA (p = 0.006). Overall, these results indicate that expression of HYAL-2, but not plasma HA nor HAS-3, is enhanced in patients with COPD compared to (non)smoking controls. Furthermore, HA was not associated with clinical outcomes, yet, cardiovascular risk might play a role in its systemic regulation in stable COPD.Kiki Waeijen-SmitNiki L. ReynaertRosanne J. H. C. G. BeijersSarah Houben-WilkeSami O. SimonsMartijn A. SpruitFrits M. E. FranssenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kiki Waeijen-Smit Niki L. Reynaert Rosanne J. H. C. G. Beijers Sarah Houben-Wilke Sami O. Simons Martijn A. Spruit Frits M. E. Franssen Alterations in plasma hyaluronic acid in patients with clinically stable COPD versus (non)smoking controls
description	Abstract Hyaluronic acid (HA) is a key component of the extracellular matrix. HA and its metabolism are suggested to be altered in the lungs of patients with chronic obstructive pulmonary disease (COPD). The present study explored systemic HA, and its metabolic regulators, in patients with clinically stable COPD and smoking and non-smoking controls. Furthermore, associations of HA with acute exacerbations (AECOPD), airway-related hospitalizations, systemic inflammation and cardiovascular risk were studied. In total, 192 patients with moderate to very severe COPD [aged 62.3 y (± SD 7.0)], 84 smoking controls [aged 61.8 y (± 5.7)], and 107 non-smoking controls [aged 60.1 y (± 7.0)] were included. Plasma HA was reduced in patients with COPD compared to non-smoking controls (p = 0.033), but was comparable after adjusting for age and sex. Expression of HAS-3 did not differ between groups, but was substantially less detectable in more patients with COPD than (non)smoking controls (p < 0.001). Expression of HYAL-2 was enhanced in patients with COPD versus smoking (p = 0.019) and non-smoking (p < 0.001) controls, also in the age- and sex- adjusted model (p < 0.001). Plasma HA was not associated with AECOPD, airway-related hospitalizations in the previous year, or systemic inflammation in COPD. Arterial pulse wave velocity explained some of the variance (< 10%) in plasma HA (p = 0.006). Overall, these results indicate that expression of HYAL-2, but not plasma HA nor HAS-3, is enhanced in patients with COPD compared to (non)smoking controls. Furthermore, HA was not associated with clinical outcomes, yet, cardiovascular risk might play a role in its systemic regulation in stable COPD.
format	article
author	Kiki Waeijen-Smit Niki L. Reynaert Rosanne J. H. C. G. Beijers Sarah Houben-Wilke Sami O. Simons Martijn A. Spruit Frits M. E. Franssen
author_facet	Kiki Waeijen-Smit Niki L. Reynaert Rosanne J. H. C. G. Beijers Sarah Houben-Wilke Sami O. Simons Martijn A. Spruit Frits M. E. Franssen
author_sort	Kiki Waeijen-Smit
title	Alterations in plasma hyaluronic acid in patients with clinically stable COPD versus (non)smoking controls
title_short	Alterations in plasma hyaluronic acid in patients with clinically stable COPD versus (non)smoking controls
title_full	Alterations in plasma hyaluronic acid in patients with clinically stable COPD versus (non)smoking controls
title_fullStr	Alterations in plasma hyaluronic acid in patients with clinically stable COPD versus (non)smoking controls
title_full_unstemmed	Alterations in plasma hyaluronic acid in patients with clinically stable COPD versus (non)smoking controls
title_sort	alterations in plasma hyaluronic acid in patients with clinically stable copd versus (non)smoking controls
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/68d5b36613634f9f9ad5b73c168b0ad3
work_keys_str_mv	AT kikiwaeijensmit alterationsinplasmahyaluronicacidinpatientswithclinicallystablecopdversusnonsmokingcontrols AT nikilreynaert alterationsinplasmahyaluronicacidinpatientswithclinicallystablecopdversusnonsmokingcontrols AT rosannejhcgbeijers alterationsinplasmahyaluronicacidinpatientswithclinicallystablecopdversusnonsmokingcontrols AT sarahhoubenwilke alterationsinplasmahyaluronicacidinpatientswithclinicallystablecopdversusnonsmokingcontrols AT samiosimons alterationsinplasmahyaluronicacidinpatientswithclinicallystablecopdversusnonsmokingcontrols AT martijnaspruit alterationsinplasmahyaluronicacidinpatientswithclinicallystablecopdversusnonsmokingcontrols AT fritsmefranssen alterationsinplasmahyaluronicacidinpatientswithclinicallystablecopdversusnonsmokingcontrols
_version_	1718389449449013248

Alterations in plasma hyaluronic acid in patients with clinically stable COPD versus (non)smoking controls

Ejemplares similares